LTF

The leading and most trusted provider of vegan certification in North America gives TurtleTree's sustainable lactoferrin, LF+, the stamp of approval, setting new industry standards WOODLAND, Calif., Feb. 14, 2024 /PRNewswire/ -- TurtleTree, a pioneer in sustainable nutrition, and Vegan Action, the most recognized vegan certification provider in the U.S. today announced the official vegan certification of TurtleTree's animal-free sustainable lactoferrin, LF+. This milestone establishes TurtleTree as the first precision fermentation dairy company globally to obtain vegan certification, and the first ever to receive the Certified Vegan logo in the 24 years it's been administered. In taking this step, TurtleTree has solidified its unwavering commitment to animal welfare as well as meeting the evolving demands of conscious consumers. Continue Reading TurtleTree CEO and Co-Founder Fengru Lin and TurtleTree's world-first vegan-certified lactoferrin, LF+ While most precision fermentation products don't involve animal products or byproducts, their bioidentical nature and the origins of the genetic codes required in production can make interpretations complex, particularly when adhering to vegan standards originally designed for plant-based products. Regulatory approval also demands extensive safety testing, and some companies may opt for quicker, cheaper animal studies, and preclude their products from obtaining vegan certification. This is a hot-button issue and potentially the reason most precision fermentation companies haven't pursued official certification, despite stating they are vegan and animal-free. Turtletree has taken a pioneering step by securing vegan certification for its bioidentical dairy protein, LF+, confirming strict adherence to the highest ethical standards. In turn, the company aims to set a precedent that can help create a standardized definition of veganism in the context of precision fermentation. TurtleTree's certification by Vegan Action adhered to rigorous criteria, guaranteeing the exclusion of animal products, byproducts, and animal testing. LF+ is now the only vegan lactoferrin on the market, challenging the dominance of lactoferrin sourced exclusively from cows. As the global vegan food market is projected to reach $36 billion by 2031, the demand for certified vegan products continues to surge. With this certification, LF+ is well-positioned to cater to this growing market and support large food and beverage companies seeking innovative, vegan-certified ingredients. Fengru Lin, CEO and Co-Founder of TurtleTree, emphasizes TurtleTree's dedication to aligning words with actions: "With this certification, we are putting words into action and allowing that action to be validated by a third party. We want to build a food system that is sustainable and enables animals to live happier and healthier lives. As conscious consumers increasingly prioritize ethical choices, we aim to provide food and beverage brands with the unwavering confidence that our products align seamlessly with those evolving values." Krissi Vandenberg, Director of Vegan Action, celebrates this alternative protein milestone. "We were thrilled to get TurtleTree's product Vegan Certified because of the clear benchmark this sets for the rest of the industry. TurtleTree's dedication to ethical practices and transparency is commendable and will undoubtedly inspire other precision fermentation companies. This certification demonstrates the tangible steps companies can take to validate and communicate their values to customers, underlining a collective commitment to ethical standards." The Certified Vegan logo from Vegan Action now adorns LF+ packaging, showcasing TurtleTree's commitment to transparency and validating its claims through independent third-party assessment. About TurtleTree TurtleTree is a biotechnology company creating a new generation of nutrition—one that's better for the planet, animals, and people everywhere. Harnessing cutting-edge precision fermentation technology, TurtleTree is creating better-for-you ingredients sustainably and affordably, with benefits that enhance not only plant-based foods but a wide variety of everyday food products. About Vegan Action Vegan Action is a 501(c)3 nonprofit organization working to eliminate animal suffering, reduce environmental impacts, and improve human health through a vegan diet. Vegan Action is a provider of vegan certification via the Certified Vegan Logo. Distributed and recognized globally, the logo is a registered trademark for products and ingredients that do not contain animal products or byproducts and that have not been tested on animals. For more information, please visit TurtleTree's website and follow them on Instagram, Twitter, and LinkedIn. Graphics: Available here SOURCE TurtleTree

Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays SAN DIEGO, CA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that the Company has signed an agreement with contract manufacturer Auer Precision for the production of its two FDA-cleared diagnostic assays designed for point-of-care diagnosis of Dry Eye Disease (DED). The partnership will enable scaling of production quantities of the assays to meet demand for the tests in a cost-effective way. Until this agreement, the Company has been manufacturing both its ocular T-POC TOTAL IgE Immunoassay and T-POC LACTOFERRIN Immunoassay FDA-cleared Kits in-house. With the assay design validated and sales taking place through its commercialization partner Verséa Ophthalmics, AXIM sought a partner who had a proven track record of best-in-class diagnostic manufacturing who was willing to invest in the necessary infrastructure to support the scaled growth of production of the tests. Auer, whose facilities are ISO Certified has been producing medical diagnostics including later flow assays since 1972, is a market leader in both high precision and next gen product development, making the company a great fit as AXIM’s manufacturing partner. Through the agreement Auer will begin producing both tests as soon as possible to meet the demand of clinicians nationwide as well as scale production as necessary in the coming months. “AXIM is a research and development company and from a strategic standpoint, selecting a great partner for manufacturing will enable us to focus on what we do best while generating revenue on our already proven tests in the most efficient way,” said John Huemoeller II, CEO of AXIM Biotechnologies. “While we have been able to meet the demands of regulatory agencies and some orders by in-house manufacturing, the economies of scale afforded by working with a reputable firm like Auer make the partnership a no-brainer. They were quick to prove their understanding of our tests and firm in their ability to scale production to meet our needs now and in the future. We look forward to a long and fruitful relationship with them.” AXIM’s diagnostic assays address a critical unmet need in ophthalmological healthcare where approximately 344 million people worldwide suffer from DED but many clinicians struggle to properly diagnose the disease due to insufficient diagnostic tools. Both of AXIM’s tests are revolutionary in that they were designed to be administered at the point-of-care and render results in nine minutes. The allergen-specific immunoglobulin E (IgE) assay quantitatively measures IgE in samples, enabling clinicians to differentiate between the underlying causes of a patient’s eye condition and prescribe treatment accordingly. Its other test measures levels of Lactoferrin, a protein that exhibits a unique combination of antimicrobial, antiviral and anti-inflammatory properties. Measuring Lactoferrin levels in patients enables clinicians to directly correlate low levels to dry eye disease caused by aqueous deficiency and the severity of DED can be determined by the Lactoferrin level. Low Lactoferrin levels indicate DED and depressed ocular immunity, which may represent an increased surgical risk and of contact lens intolerance. For more information on AXIM’s diagnostic solutions or to speak with someone at AXIM’s commercialization partner Verséa about adding these innovative solutions to your clinic, please visit: https://www.versea.com/divisions/ophthalmics/ About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com. About Auer Precision Auer Precision has provided product support and manufacturing solutions for the medical and life sciences industry for over 25 years. Our Medical Products Group works with customers from initial design and prototyping through full commercial realization, including Tier 1 assembly/packaging and supply chain management. We specialize in die-cut (stamping) and automated solutions for disposable microfluidic and lateral flow. Forward-Looking Statements The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. CONTACT Kyle Porter CMW Media P. 858-221-8001 axim@cmwmedia.com AXIM Corporate 6191 Cornerstone Ct., Ste. 114 San Diego, CA 92121, USA P. 858-923-4422 Investor Relations investors@aximbiotech.com 888-759-0844

Axim claims there can be enough alpha-synuclein in a person’s tears to deliver a result in less than 10 minutes, without the use of complex lab hardware. If the eyes are windows into the soul, Axim Biotechnologies believes that tears can provide a peek into the inner workings of the brain—and potentially carry with them the signs of Parkinson’s disease. The company announced that it has developed a rapid, point-of-care assay that could be used for the neurodegenerative condition, by searching for abnormal formations of a key brain protein within a single teardrop. Known as alpha-synuclein, the protein biomarker has been described as a possible driver of Parkinson’s, as it misfolds and causes clumps to form in the disease’s characteristic Lewy bodies that cluster within the brain.  According to a separate study published earlier this year in The Lancet Neurology, researchers found that the presence of abnormal alpha-synuclein proteins within a person’s cerebrospinal fluid was highly accurate in predicting whether or not they had Parkinson’s disease when compared with healthy volunteers. But now, Axim claims it can reach a diagnosis without requiring a painful spinal tap to collect a sample. The company said there can be enough alpha-synuclein in a person’s tear fluid to deliver a quantitative result in less than 10 minutes, without the use of complex lab hardware—though Axim did not provide data on the test’s accuracy. “With this new assay, Axim has immediately become a stakeholder in the Parkinson’s disease community, and through this breakthrough, we are making possible new paradigms for better clinical care, including earlier screening and diagnosis, targeted treatments and faster, cheaper drug development,” CEO John Huemoeller said in the company’s release. Axim previously billed itself as a cannabinoid drug developer and once maintained a pipeline of topical-, capsule- and chewing gum-based treatments for conditions that spanned irritable bowel syndrome, psoriasis, nausea and more. It has since transitioned into a diagnostic test maker, with assays aimed at dry eye disease, as well as for COVID-19 and cancer. The San Diego-based company acquired Advanced Tear Diagnostics in late 2021, with a deal that covered two FDA-cleared tests for dry eye disease. They included a lateral flow diagnostic for point-of-care use that measures the level of lactoferrin proteins in tear fluid, which work to protect the surface of the eye. The second test looks for ocular immunoglobulin E, an immune system biomarker linked to allergies. Axim said that low lactoferrin levels have also been linked to Parkinson’s disease and that the assay can be used alongside its alpha-synuclein test. “Our proven expertise in developing tear-based diagnostic tests has led to the development of this test in record speed, and I’m extremely proud of our scientific team for their ability to expand our science to focus on such an important focus area as Parkinson’s,” Huemoeller said in the company’s announcement.